Abstract

HTA110 Acceptability of Surrogate Endpoints by Health Technology Assessment Bodies: Results from a Systematic Review of Transparency Committee Assessments in France

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
PHP293 - Understanding Health Technology Assessment (HTA) Bodies in Major Latin-American (LATAM) Markets: Systematic Evaluation in 5 Latam Countries
M Nanavaty ... M Mwamburi
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 19
M Nanavaty, et. al.M Nanavaty ... M Mwamburi
31 Oct 2016
OP137 A Qualitative Exploration Of The National Institute For Health And Care Excellence’s Impact On International Health Technology Assessment
Nadine Henderson ... Martina Garau
International Journal of Technology Assessment in Health Care | VOL. 39
Nadine Henderson, et. al.Nadine Henderson ... Martina Garau
01 Dec 2023
VP216 Health Technology Assessment's Balance Between Additional Data, Adoption, And Patient Access
Parashar Patel ... Michael Cangelosi
International Journal of Technology Assessment in Health Care | VOL. 33
Parashar Patel, et. al.Parashar Patel ... Michael Cangelosi
01 Jan 2017
HS2 - Medication Adherence as a Value Message: A Rarity In Evaluation Assessments Submitted to Major Hta Bodies
S Singla ... G Outteridge
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. 17
S Singla, et. al.S Singla ... G Outteridge
26 Oct 2014
View more papers

More From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Paper Title
Journal
Date
Author
How many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses?
Reza Yaesoubi
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Reza YaesoubiReza Yaesoubi
06 Jul 2024
Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism
Darius N Lakdawalla ... Hong-Hanh Nguyen
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Darius N Lakdawalla, et. al.Darius N Lakdawalla ... Hong-Hanh Nguyen
06 Jul 2024
Generating utilities for the CS-Base: a novel, generic, and patient-centered health-outcome measure
Xin Zhang ... Paul Fm Krabbe
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Xin Zhang, et. al.Xin Zhang ... Paul Fm Krabbe
06 Jul 2024
EQ-5D-5L population scores in mainland China: results from a nationally representative survey 2021
Qiang Yao ... Chaojie Liu
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | VOL. -
Qiang Yao, et. al.Qiang Yao ... Chaojie Liu
06 Jul 2024
View more papers